Focused on AIDD (Artificial Intelligence Drug Discovery) as its core technological engine, Huitai Biomedicine leverages proprietary core algorithms and a global intellectual property portfolio to precisely target the unmet clinical needs in fibrotic diseases. The company is engaged in the research and development of FIC (first-in-class) innovative drugs and full-chain commercialization, while tackling global clinical challenges in the field of anti-aging. At present, the company’s first drug candidate developed with the assistance of AIDD has been approved to enter pivotal clinical trials.